HRTX at a glance
HERON THERAPEUTICS, INC. /DE/ (HRTX, SEC CIK 818033) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as August 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), HERON THERAPEUTICS, INC. /DE/ (HRTX) reported revenue of $154.9 million (up 7.4% from FY2024) and a net loss of $20.2 million. Diluted EPS was -$0.12.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding HERON THERAPEUTICS, INC. /DE/ (HRTX) shares worth $15.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $154.9M
- +7.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $15.0M · −1 vs prior quarter
- Latest 8-K
- Sep 29, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Profitability, margin percentages, and quarterly earnings figures not provided
- APONVIE pass-through reimbursement expired March 31, 2026
- APONVIE permanent J-code approved effective April 1, 2026
- SUSTOL commercial availability ending September 30, 2026; CINVANTI patent claims invalidated or found not infringed
AI summary of the HRTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Exclusive U.S. commercialization rights for multiple products, with sublicensing and worldwide manufacturing rights
- Regulatory and sales milestones, royalties, and expense reimbursements create future cash obligations tied to product performance
Item 1.01: Entry into a Material Definitive Agreement
- Tax Benefit Preservation Plan extended three years, with final expiration moved from August 14, 2026 to August 14, 2029
- Longer protection period helps preserve Heron’s tax attributes against ownership changes
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 results announced for periods ended June 30, 2026
- Investor-relevant financial details contained in furnished Exhibit 99.1 earnings release
Item EX-99.1: Item EX-99.1
- Q2 net revenue $37.7M, up 1.3% year-over-year; six-month revenue declined 4.9% to $72.4M
- Acute Care growth offset Oncology weakness: APONVIE +73.6% and ZYNRELEF +35.0%, while CINVANTI fell 9.7%
AI summaries of HRTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HRTX
Don't miss the next HRTX filing
- Alerts as it files. A push when HRTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HRTX, by share count.
- Ask anything. An AI agent that reads every HRTX filing and answers with sources.
HRTX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hensley Mark Earl | M | Aug 6, 2026 | 31,250 | - |
| Hensley Mark Earl | F | Aug 6, 2026 | 8,888 | $0.50 |
| Hensley Mark Earl | M | Aug 6, 2026 | 31,250 | - |
| Hensley Mark Earl | M | Jul 31, 2026 | 11,769 | - |
| Collard Craig A | M | Jul 31, 2026 | 34,789 | - |
| Duarte Ira | M | Jul 31, 2026 | 11,694 | - |
| Duarte Ira | M | Jul 31, 2026 | 11,694 | - |
| Duarte Ira | F | Jul 31, 2026 | 3,326 | $0.50 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $144.3M | $154.9M |
| Gross Profit | - | $105.6M | $113.6M |
| Operating Income | - | -$11.5M | -$2.5M |
| Net Income | - | -$13.6M | -$20.2M |
| Gross Margin | - | 73.2% | 73.3% |
| Op. Margin | - | -8.0% | -1.6% |
| Net Margin | - | -9.4% | -13.0% |
| Balance Sheet | |||
| Total Assets | - | $233.1M | $255.9M |
| Equity | - | -$33.7M | $14.3M |
| ROE | - | 40.4% | -140.9% |
| Per Share | |||
| EPS | $-0.80 | $-0.09 | $-0.12 |
| Cash Flow | |||
| Operating CF | - | -$22.5M | -$27.6M |
| CapEx | $1.5M | $1.7M | $317K |
Source: XBRL data in HERON THERAPEUTICS, INC. /DE/ (HRTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HRTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $15.0M |
| Q1 2026 | 25 | $32.7M |
| Q4 2025 | 22 | $57.0M |
| Q3 2025 | 23 | $57.3M |
| Q2 2025 | 24 | $88.4M |
| Q1 2025 | 23 | $57.9M |
| Q4 2024 | 17 | $30.1M |
| Q3 2024 | 15 | $32.0M |
- AQR Capital Management+912.3K (+142%)
- BlackRock+444.3K (+4%)
- Goldman Sachs Group+272.8K (+26%)
- Vanguard Portfolio Management LLC+271.2K (+21%)
- FMR LLC (Fidelity)+168.6K (+290%)
- Millennium Management−3.56M (-47%)
- D.E. Shaw & Co−2.48M (-95%)
- State Street Corp−615.1K (-16%)
- Morgan Stanley−401.7K (-78%)
- Renaissance Technologies LLC−211.4K (-12%)
- Citadel Advisors LLC−759.3K
- NICOLET BANKSHARES INC−16.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 173 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HRTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 4 | Aug 10, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
HRTX SEC filings: frequently asked questions
Which institutions hold HRTX stock?
As of June 30, 2026, the largest HERON THERAPEUTICS, INC. /DE/ (HRTX) holders among the 13F filers tracked by SignalX were BlackRock ($4.5 million), Vanguard Capital Management LLC ($3.3 million), Millennium Management ($1.7 million), State Street Corp ($1.4 million), Vanguard Portfolio Management LLC ($675,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HRTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), HERON THERAPEUTICS, INC. /DE/ (HRTX) reported revenue of $154.9 million (up 7.4% from FY2024) and a net loss of $20.2 million. Diluted EPS was -$0.12. The figures come from the XBRL data in the 10-K.
What did HRTX report in its latest 8-K?
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K on September 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Exclusive U.S. commercialization rights for multiple products, with sublicensing and worldwide manufacturing rights.
What are the latest HRTX SEC filings?
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on August 10, 2026.
What is HRTX's SEC CIK number?
HERON THERAPEUTICS, INC. /DE/ (HRTX)'s SEC Central Index Key (CIK) is 818033. EDGAR lists every HRTX filing under that number.
Ask anything about HRTX
The research agent reads HRTX's filings, financials, insider trades and 13F holders, then answers with sources.